Regorafenib + Nivolumab + Docetaxel + Paclitaxel + Irinotecan + Trifluridine/Tipracil
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastro-Oesophageal Cancer
Conditions
Gastro-Oesophageal Cancer
Trial Timeline
Jun 1, 2021 → Jun 1, 2026
NCT ID
NCT04879368About Regorafenib + Nivolumab + Docetaxel + Paclitaxel + Irinotecan + Trifluridine/Tipracil
Regorafenib + Nivolumab + Docetaxel + Paclitaxel + Irinotecan + Trifluridine/Tipracil is a phase 3 stage product being developed by Bristol Myers Squibb for Gastro-Oesophageal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04879368. Target conditions include Gastro-Oesophageal Cancer.
What happened to similar drugs?
1 of 1 similar drugs in Gastro-Oesophageal Cancer were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04879368 | Phase 3 | Active |
Competing Products
4 competing products in Gastro-Oesophageal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD8931 + Placebo + Paclitaxel | AstraZeneca | Phase 2 | 27 |
| Esomeprazole | AstraZeneca | Approved | 43 |
| AZD4547 + paclitaxel | AstraZeneca | Phase 2 | 27 |
| Bemarituzumab + Flot regimen | Amgen | Phase 2 | 27 |